HC Wainwright Issues Pessimistic Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Zevra Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($0.32) per share for the year, down from their previous estimate of ($0.23). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.58 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.51 EPS.

A number of other brokerages have also recently weighed in on ZVRA. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group lifted their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Finally, Guggenheim lifted their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $8.35 on Monday. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The stock has a market cap of $451.87 million, a PE ratio of -4.24 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a fifty day moving average price of $7.92 and a 200 day moving average price of $8.17.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Zevra Therapeutics during the fourth quarter worth about $53,000. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics during the fourth quarter worth about $94,000. XTX Topco Ltd acquired a new position in Zevra Therapeutics during the third quarter worth about $94,000. Intech Investment Management LLC acquired a new position in Zevra Therapeutics during the third quarter worth about $95,000. Finally, Squarepoint Ops LLC grew its position in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after buying an additional 4,384 shares during the period. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zevra Therapeutics

In other news, EVP Joshua Schafer sold 10,500 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by company insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.